Summary
Johnson & Johnson (JNJ) announced a significant addition to its Board of Directors with the appointment of Dr. Nadja West, a retired United States Army lieutenant general and former United States Army Surgeon General. This appointment, effective immediately as of December 3, 2020, brings a wealth of experience in leadership and healthcare strategy to the company's governance. Dr. West's expertise is particularly relevant given Johnson & Johnson's extensive involvement in pharmaceuticals, medical devices, and consumer health products, including significant contributions to public health and medical innovation. Dr. West will also be a member of the Board's Science, Technology & Sustainability Committee starting January 1, 2021. This strategic placement will leverage her background to inform decisions related to the company's innovation pipeline, technological advancements, and its commitment to sustainable practices. As a non-employee Director, her compensation will align with standard practices outlined in the company's proxy statement, ensuring alignment with shareholder interests. This appointment signals a focus on strengthening the Board's capabilities in critical areas for JNJ's future growth and impact.
Key Highlights
- 1Johnson & Johnson appointed Dr. Nadja West to its Board of Directors, effective immediately.
- 2Dr. West is a retired United States Army lieutenant general and former United States Army Surgeon General.
- 3She will serve on the Board’s Science, Technology & Sustainability Committee, starting January 1, 2021.
- 4The appointment brings significant leadership and healthcare strategy experience to the Board.
- 5Dr. West's role is as a non-employee Director.
- 6Compensation for Dr. West will follow the Company's standard non-employee Director compensation plan as detailed in the 2020 Proxy Statement.